AR070539A1 - Inhibidores de la actividad de proteina tirosina quinasa - Google Patents
Inhibidores de la actividad de proteina tirosina quinasaInfo
- Publication number
- AR070539A1 AR070539A1 ARP090100693A ARP090100693A AR070539A1 AR 070539 A1 AR070539 A1 AR 070539A1 AR P090100693 A ARP090100693 A AR P090100693A AR P090100693 A ARP090100693 A AR P090100693A AR 070539 A1 AR070539 A1 AR 070539A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- group
- independently selected
- integer
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente se refiere a compuestos que inhiben la actividad de la proteína tirosina quinasa. En particular se refiere a compuestos que inhiben la actividad de la proteína tirosina quinasa de receptores del factor de crecimiento, dando por resultado la inhibicion de la senalizacion de receptores, por ejemplo, la inhibicion de la senalizacion del receptor VEGF. También proporciona compuestos, composiciones y métodos para tratar enfermedades y condiciones patologicas proliferativas celulares y enfermedades, trastornos y condiciones patologicas oftalmologicas. Reivindicacion 1: Un compuesto de la formula (1) y N-oxidos, hidratos, solvatos, sales farmacéuticamente aceptables, profármacos y complejos de ellos, y mezclas racémicas y escalémicas, sus diastereomeros y enantiomeros, en donde D está seleccionado del grupo que consiste en un sistema de anillos aromáticos, heteroaromáticos, cicloalquilos o heterocíclicos, cada uno de los cuales está opcionalmente sustituido con 1 a 5 seleccionados de modo independiente R38; M es un resto heterocíclico fusionado opcionalmente sustituido; Z es -O-; Ar es un sistema de anillos aromáticos de 5 a 7 miembros, que está opcionalmente sustituido con 0 a 4 grupos R2: y G es un grupo B-L-T, en donde B es -N(R13)- o -C(=S)-; L está seleccionado del grupo que consiste en -C(=O)N(R13)-, -C(=O)alquil C0-1-C(=O)N(R13)-, y -C(=O)-, en donde un grupo alquilo del grupo L antes mencionado está opcionalmente sustituido; y T está seleccionado del grupo que consiste en -alquilo C0-5, -alquil C0-5-Q, -O-alquil C0-5-Q, -O-alquilo C0-5, -C(=S)-N(R13)-alquil C0-5-Q, -alquil C0-5-S(O)2-Q y -C(=S)-N(R13)-alquilo C0-5, en donde cada alquilo C0-5 está opcionalmente sustituido; en donde cada R38 está seleccionado, de modo independiente, del grupo que consiste en halo, alquilo C1-C6 opcionalmente sustituido, -alquil C0-6-(heterociclo opcionalmente sustituido), -alquenil C2-6=N-heterociclo-alquilo C1-6 opcionalmente sustituido, -CH=N-heterociclo opcionalmente sustituido, -(CH2)jNR39(CH2)nR36, -C(O)(CH2)jNR39(CH2)nR36, -(CH2)jNR39(CH2)i[O(CH2)i]x(CH2)jR99, -(CH2)jNR39C(O)(CH2)jO(CH2)jOR3, -(CH2)jNR39(CH)(CH3)(CH2)jR99 y -(CH2)jNR39(CH2)jCOOH; en donde cada j es un numero entero que va, de modo independiente, de 0 a 4, n es un numero entero que va de 0 a 6, x es un numero entero que va de 0-6, cada i es, de modo independiente, 2 o 3, y los restos -(CH2)n- de los grupos anteriores R38 están opcionalmente sustituidos con alquilo C1-6; R36 es H o -(CH2)n3OR37; en donde n3 es un numero entero que va de 0 a 6; con la condicion de que, cuando R36 y R39 están unidos ambos al mismo nitrogeno, entonces R36 y R39 no estén ambos unidos al nitrogeno directamente a través de un oxígeno; cada R37 está seleccionado, de modo independiente, de H, alquilo C1-6, -(CH2)nO(CH2)aO-alquilo C1-6, -(CH2)nCH(NH)(CH2)nO-alquilo C1-6, -(CH2)nCH(NH)(CH2)nalquilo C1-6, -(CH2)nO(CH2)aO-cicloalquiIo C3-10, -(CH2)nCH(NH)(CH2)nO-cicloalquilo C3-10 y -(CH2)nCH(NH)(CH2)ncicloalquilo C3-10, en donde cada n es un numero entero que va, de modo independiente, de 0 a 6 y a es un numero entero que va de 2 a 6, en donde los restos de alquilo y cicloalquilo de los grupos anteriores R37 están opcionalmente sustituidos con uno o varios sustituyentes seleccionados de modo independiente; R39 está seleccionado del grupo que consiste en H, alquilo C1-6, -SO2-alquilo C1-6, -C(O)-alquilo C1-6, -C(O)O-alquilo C1-6, -C(O)-alquil C1-6-NR3R3, -alquil C1-C6-O-alquilo C1-6, -C(O)(CH2)0-4O(CH2)1-4Oalquilo C1-6, -C(O)-alquil C1-6-OH, -C(O)-CF3 y -C(O)CH[CH(alquil C1-6)2]NR3R3 y un grupo protector usado para proteger grupos amino secundarios, con la condicion de que, cuando R36 y R39 están unidos ambos al mismo nitrogeno, entonces R36 y R39 no estén ambos unidos al nitrogeno directamente a través de un oxígeno; R99 en cada aparicion es, de modo independiente, -H, -NH2 u -OR3; R2 en cada aparicion está seleccionado, de modo independiente, de -H y halogeno; cada R3 está seleccionado, de modo independiente, del grupo que consiste en -H y R4; R4 es alquilo C1-6; cada R13 está seleccionado, de modo independiente, del grupo que consiste en -H, -C(O)NR3R3 y alquilo C1-6; Q es un sistema de anillos de tres a diez miembros, opcionalmente sustituido con cero a cuatro de R20; cada R20 está seleccionado, de modo independiente, del grupo que consiste en -H, halogeno, trihalometilo, -OR3, -S(O)0-2R3, -S(O)2NR3R3, -C(O)OR3, -C(O)NR3R3, -(CH2)0-5(heteroarilo), alquilo C1-6, -(CH2)nP(=O)(alquilo C1-6)2, en donde n es un numero entero que va de 0 a 6, y el heteroarilo y el alquilo C1-6 están opcionalmente sustituidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3400508P | 2008-03-05 | 2008-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070539A1 true AR070539A1 (es) | 2010-04-14 |
Family
ID=41055503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100693A AR070539A1 (es) | 2008-03-05 | 2009-02-27 | Inhibidores de la actividad de proteina tirosina quinasa |
| ARP100104383A AR079208A2 (es) | 2008-03-05 | 2010-11-26 | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104383A AR079208A2 (es) | 2008-03-05 | 2010-11-26 | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8729268B2 (es) |
| EP (2) | EP2332536A1 (es) |
| JP (2) | JP2011513339A (es) |
| KR (2) | KR20100132068A (es) |
| CN (2) | CN102161663B (es) |
| AR (2) | AR070539A1 (es) |
| AU (2) | AU2009221583B2 (es) |
| BR (2) | BRPI0908573A2 (es) |
| CA (2) | CA2763168A1 (es) |
| CO (1) | CO6290684A2 (es) |
| IL (2) | IL207946A0 (es) |
| MX (1) | MX2010009729A (es) |
| NZ (2) | NZ589336A (es) |
| RU (2) | RU2533827C2 (es) |
| SG (1) | SG182146A1 (es) |
| TW (2) | TWI438205B (es) |
| UA (2) | UA100262C2 (es) |
| WO (1) | WO2009109035A1 (es) |
| ZA (2) | ZA201005868B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR070539A1 (es) * | 2008-03-05 | 2010-04-14 | Methylgene Inc | Inhibidores de la actividad de proteina tirosina quinasa |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| BR112012004843A2 (pt) * | 2009-09-03 | 2019-09-24 | Allergan Inc | compostos como moduladores de tirosina cinase |
| JP2013525286A (ja) * | 2010-04-16 | 2013-06-20 | メチルジーン・インコーポレイテッド | タンパク質チロシンキナーゼ活性の阻害剤 |
| TWI492949B (zh) * | 2010-06-09 | 2015-07-21 | Abbvie Bahamas Ltd | 結晶型激酶抑制劑 |
| TWI482770B (zh) * | 2010-06-09 | 2015-05-01 | Abbvie Bahamas Ltd | 結晶型激酶抑制劑 |
| MX2012014386A (es) * | 2010-06-09 | 2013-05-01 | Abbvie Inc | Formas cristalinas de inhibidores de cinasa. |
| CN103052640B (zh) * | 2010-08-27 | 2017-06-30 | 默克专利股份公司 | 呋喃并吡啶衍生物 |
| MX2013003101A (es) * | 2010-09-17 | 2013-09-26 | Purdue Pharma Lp | Compuestos de piridina y sus usos. |
| BRPI1004176A2 (pt) * | 2010-10-25 | 2015-08-11 | Univ Rio De Janeiro | Compostos aril e/ou hetero aril uréias funcionalizados; processo de síntese desses composto; composição farmacêutica contendo tais compostos e usos |
| WO2013044360A1 (en) * | 2011-09-30 | 2013-04-04 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
| WO2013044361A1 (en) * | 2011-09-30 | 2013-04-04 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
| WO2013044362A1 (en) * | 2011-09-30 | 2013-04-04 | Methylgene Inc. | Selected inhibitors of protein tyrosine kinase activity |
| AU2015360613A1 (en) * | 2014-12-09 | 2017-06-29 | Abbvie Inc. | Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
| FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| KR102708050B1 (ko) | 2018-01-31 | 2024-09-24 | 데시페라 파마슈티칼스, 엘엘씨. | 비만 세포증의 치료를 위한 병용 요법 |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| CN114615982A (zh) | 2019-08-12 | 2022-06-10 | 德西费拉制药有限责任公司 | 用于治疗胃肠道间质瘤的瑞普替尼 |
| CN118948772A (zh) | 2019-12-30 | 2024-11-15 | 德西费拉制药有限责任公司 | 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物 |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| WO2023155777A1 (en) * | 2022-02-15 | 2023-08-24 | Beigene (Suzhou) Co., Ltd. | N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7000A (en) * | 1850-01-08 | Smut-machine | ||
| US7019A (en) * | 1850-01-15 | Improvement in obstetrical supporters | ||
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| HUP0100287A3 (en) | 1997-11-11 | 2003-04-28 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| WO1999062908A2 (en) | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| ES2223827T3 (es) | 2000-06-06 | 2005-03-01 | Pfizer Products Inc. | Derivados de tiofeno utiles como agentes anticancerigenos. |
| US20020004511A1 (en) | 2000-06-28 | 2002-01-10 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
| ATE419239T1 (de) * | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2003074529A2 (en) | 2002-03-01 | 2003-09-12 | Pfizer Inc. | iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS |
| US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| US20050065171A1 (en) | 2003-06-25 | 2005-03-24 | Shakespeare William C. | Substituted purine derivatives |
| JP2007504122A (ja) | 2003-08-29 | 2007-03-01 | ファイザー・インク | 新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体 |
| WO2005052872A1 (en) | 2003-11-21 | 2005-06-09 | Facil, Llc | Financial transaction system and method |
| WO2005073224A2 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| WO2005121125A1 (en) | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| AU2005270068B2 (en) | 2004-07-02 | 2012-04-19 | Exelixis, Inc. | C-Met modulators and method of use |
| BRPI0513405A (pt) | 2004-07-16 | 2008-05-06 | Sunesis Pharmaceuticals Inc | tienopirimidinas úteis como inibidores de aurora quinase |
| BRPI0513982A (pt) | 2004-07-30 | 2007-11-27 | Methylgene Inc | inibidores de sinalização de receptor de vegf e receptor de hgf |
| EP1827434B1 (en) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
| AU2006229343A1 (en) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
| EP1874759A4 (en) | 2005-04-06 | 2009-07-15 | Exelixis Inc | C-MET MODULATORS MODULATORS AND METHODS OF USE |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| CA2608726C (en) | 2005-05-20 | 2013-07-09 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
| BRPI0610322B8 (pt) * | 2005-05-20 | 2021-05-25 | Methylgene Inc | inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica |
| TW200740820A (en) * | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| CN101522687A (zh) * | 2006-01-30 | 2009-09-02 | 阿雷生物药品公司 | 用于癌症治疗的杂二环噻吩化合物 |
| AR060061A1 (es) | 2006-03-22 | 2008-05-21 | Methylgene Inc | Inhibidores de la actividad de la proteina tirosina quinasa |
| US7298968B1 (en) * | 2007-01-05 | 2007-11-20 | Rheem Manufacturing Company | Pumpless combination instantaneous/storage water heater system |
| MX2010002427A (es) * | 2007-08-29 | 2010-03-30 | Methylgene Inc | Inhibidores de actividad de la proteina tirosina cinasa. |
| AR070539A1 (es) * | 2008-03-05 | 2010-04-14 | Methylgene Inc | Inhibidores de la actividad de proteina tirosina quinasa |
| JP2013525286A (ja) * | 2010-04-16 | 2013-06-20 | メチルジーン・インコーポレイテッド | タンパク質チロシンキナーゼ活性の阻害剤 |
-
2009
- 2009-02-27 AR ARP090100693A patent/AR070539A1/es unknown
- 2009-02-27 CN CN201010549696.5A patent/CN102161663B/zh not_active Expired - Fee Related
- 2009-02-27 UA UAA201013462A patent/UA100262C2/uk unknown
- 2009-02-27 JP JP2010548992A patent/JP2011513339A/ja active Pending
- 2009-02-27 CA CA2763168A patent/CA2763168A1/en not_active Abandoned
- 2009-02-27 WO PCT/CA2009/000228 patent/WO2009109035A1/en not_active Ceased
- 2009-02-27 CN CN200980107358.1A patent/CN102015723B/zh not_active Expired - Fee Related
- 2009-02-27 TW TW099142241A patent/TWI438205B/zh not_active IP Right Cessation
- 2009-02-27 UA UAA201011785A patent/UA101362C2/ru unknown
- 2009-02-27 EP EP10015089A patent/EP2332536A1/en not_active Withdrawn
- 2009-02-27 BR BRPI0908573-4A patent/BRPI0908573A2/pt not_active IP Right Cessation
- 2009-02-27 NZ NZ589336A patent/NZ589336A/en not_active IP Right Cessation
- 2009-02-27 US US12/920,676 patent/US8729268B2/en not_active Expired - Fee Related
- 2009-02-27 CA CA2717816A patent/CA2717816A1/en not_active Abandoned
- 2009-02-27 RU RU2010140668/04A patent/RU2533827C2/ru not_active IP Right Cessation
- 2009-02-27 EP EP09716596A patent/EP2262815A4/en not_active Withdrawn
- 2009-02-27 KR KR1020107025059A patent/KR20100132068A/ko not_active Ceased
- 2009-02-27 AU AU2009221583A patent/AU2009221583B2/en not_active Ceased
- 2009-02-27 SG SG2012040093A patent/SG182146A1/en unknown
- 2009-02-27 BR BRPI0923670-8A patent/BRPI0923670A2/pt not_active IP Right Cessation
- 2009-02-27 MX MX2010009729A patent/MX2010009729A/es not_active Application Discontinuation
- 2009-02-27 KR KR1020107022142A patent/KR20100137495A/ko not_active Ceased
- 2009-02-27 RU RU2010145459/04A patent/RU2498988C2/ru not_active IP Right Cessation
- 2009-02-27 TW TW098106618A patent/TW200940549A/zh unknown
- 2009-02-27 NZ NZ588355A patent/NZ588355A/en not_active IP Right Cessation
-
2010
- 2010-08-17 ZA ZA2010/05868A patent/ZA201005868B/en unknown
- 2010-09-02 IL IL207946A patent/IL207946A0/en unknown
- 2010-10-01 CO CO10121775A patent/CO6290684A2/es active IP Right Grant
- 2010-10-21 IL IL208882A patent/IL208882A0/en unknown
- 2010-10-21 ZA ZA2010/07517A patent/ZA201007517B/en unknown
- 2010-11-26 AR ARP100104383A patent/AR079208A2/es unknown
- 2010-11-30 AU AU2010246540A patent/AU2010246540B2/en not_active Ceased
- 2010-12-09 US US12/964,289 patent/US8759522B2/en not_active Expired - Fee Related
-
2011
- 2011-01-21 JP JP2011010326A patent/JP5661485B2/ja not_active Expired - Fee Related
-
2014
- 2014-02-28 US US14/194,155 patent/US20140179632A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070539A1 (es) | Inhibidores de la actividad de proteina tirosina quinasa | |
| PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| PE20220905A1 (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| JOP20200338A1 (ar) | عامل وقائي أو علاجي للضمور العضلي نخاعي المنشأ | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| CL2022001950A1 (es) | Compuestos de sulfonimidamida como moduladores de nlrp3. | |
| ECSP045317A (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| TW200744587A (en) | Azaindole derivatives exhibiting PGD2 receptor antagonism | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| TW200718692A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| TW200643015A (en) | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives | |
| TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
| AR075597A1 (es) | Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas . | |
| UY28135A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| TW200734322A (en) | Indole derivatives exhibiting PGD2 receptor antagonism | |
| MY197875A (en) | Cap-dependent endonuclease inhibitors | |
| AR079467A1 (es) | Derivados heterociclicos nitrogenados de etinilo, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para tratar y/o prevenir enfermedades cognitivas o esquizofrenia. | |
| NO952208L (no) | Amin-derivater | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| PE20191784A1 (es) | Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |